IM Cannabis Corp. (NASDAQ: IMCC) stock gained by 3.01% at last close while the IMCC stock price rises by 7.19% in the after-hours session. IMC is a medicinal and adult-use recreational cannabis MCO with operations in Israel, Germany, and Canada. Over the last decade, IMCC feels that the IMC brand has been linked with quality and consistency in the Israeli medical cannabis industry.
The IMCC released confidential data from a clinical study that looked at medical cannabis therapy. The patient survey, which was designed by IMC and performed by Medicanl which is an independent, international clinical research organization specializing in cannabis research, found that seven IMC-branded medical cannabis strains were successful in treating and alleviating symptoms of seven key health conditions in a clinical group of Israeli participants. The results of the poll will be used to help patients and physicians in medical markets throughout the world tailor cannabis-based medicines to their specific illnesses.
- 81% of individuals with rheumatoid arthritis said their symptoms had improved.
- At least 60% of neuropathic pain sufferers said their symptoms had improved.
- At least 58 percent of back pain sufferers said their conditions had improved.
- At least 42% of PTSD patients said their PTSD scale had improved, as evaluated by the PCL-5, a validated questionnaire for assessing the severity of PTSD symptoms.
- According to the Pittsburgh Sleep Quality Index, 38% of insomnia patients reported better sleep quality.
- Sixty percent of oncology patients said their overall health had improved, according to the Patient Global Impression of Change assessment.
- The Pandora’s Box strain from IMC was successful in reducing appetite in patients
- All seven IMC strains enhanced sleep quality and boosted patients’ feelings of pleasure, contentment, and libido.
- There have been no documented side effects from utilizing IMC Strains.
Dr. David Meiri, Head of the Laboratory of Cancer Biology and Cannabinoid Research at the Technion, Israel Institute of Technology stated,
While medical cannabis’s general therapeutic advantages are well-known and established, research is only scraping the surface in terms of the worldwide medical community’s complete knowledge and realization of cannabinoids’ potential in curing a variety of diseases. Despite not being peer-reviewed or produced from full-scale clinical studies, the data gathered and retrieved from these sorts of clinical surveys, which are based on FDA-validated questionnaires, is readily available. It can assist clinicians and patients in better using and fine-tuning cannabis therapy for their individual medical problems.